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Abstract 
 
There remains a large gap in the literature regarding the mechanisms behind single-sided 
deafness (SSD) in humans. To begin our analysis of this issue, it is necessary to first develop an 
animal model to represent the phenotype witnessed among human patients. We used a transgenic 
mouse that expresses the human diphtheria toxin receptor (DTR) in cochlear hair cells and 
injected different concentrations of diphtheria toxin (DT) into the posterior semi-circular canal 
(PSCC) of the left ear of the adult mouse to ablate hair cells and thereby potentially model the 
rapid onset typically seen in the human condition of SSD. Using auditory brainstem response 
(ABR) testing, we identified appropriate hearing thresholds for 8 kHz, 16 kHz, and 32 kHz tones 
and considered cochlear damage to be successful when the threshold was greater than 90 dB 
SPL. Mice exposed to 0.1 mg/ml and 0.05 mg/ml concentrations of DT during PSCC surgery 
produced waveforms representing unilateral deafness. With the development of this novel model, 
we subsequently tested the effects of SSD on central auditory circuit plasticity. One measure of 
that plasticity is the expression of muscarinic acetylcholine receptors, a neurotransmitter receptor 
thought to be involved in cerebral cortex plasticity following sensory deprivation in other animal 
models. Using radio-ligand binding techniques, we measured the expression of muscarinic 
receptors in the primary auditory cortex (A1) and found a strong trend towards a difference in 
receptor expression (p = 0.0865) between the contralateral and ipsilateral hemispheres in the 0.1 
mg/ml DT dosed mouse. This knowledge of neuroplasticity in A1 after SSD onset will 
eventually contribute to better treatment outcomes.  
 
Keywords: acetylcholine, auditory brainstem response, diphtheria toxin, muscarinic receptors, 
radioligand binding, single-sided deafness  
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Introduction 
 
Sudden onset, profound unilateral sensorineural hearing loss, or single-sided deafness 
(SSD) is common (60,000 cases annually in US). Permanent SSD leads to listener disability and 
long-term challenges with sound localization and speech perception. 
SSD affects 3-8% of the general population. This life-span deficit occurs in 0.5/1000 
newborns (Kral et al., 2013; Watkin & Baldwin, 2012), 2–5/1000 children (Hassepass et al., 
2013), and 1/10,000 adults (Vincent et al., 2015). In the US, nearly 60,000 people acquire SSD 
each year (Weaver, 2015). The etiology is unknown and may result from sudden inner ear viral 
inflammation or ischemia. Untreated children are at risk for speech delays and cognitive deficits  
(Sharma et al., 2016). Usami et al. (2017) reported SSD to impact approximately 7.9-13.3% of 
the population in the United States. This number has even been classified as an underestimate in 
some cases, as many of these studies are based on self-reporting (Agrawal et al., 2008). Both 
children and adults can experience unilateral hearing loss so profound as to be classified as SSD. 
Furthermore, considering the aging population and the increase in the use of personal listening 
devices, this number is expected to increase over time.   
Hearing loss can be a disabling condition. It has become a societal problem as it impacts 
overall health care costs and general quality of life for the sufferer. Sudden and rapid 
presentations of deafness also characterize SSD, making gradual adjustment to the new sensation 
and stimulus presentation extremely challenging. This change in stimulus presentation can be 
frustrating and impact social well-being and confidence.  
Currently, there exists an incomplete understanding of the underlying etiology of SSD as 
well as optimized treatments (Van Zon et al., 2015; Kitterick et al., 2015; Bishop et al.; 2010). 
We attempted to contribute to the growing literature investigating SSD to improve prevention 
strategies, accurate diagnosis, effective treatments, and overall quality of life. Tertiary prevention 
is especially of interest in our efforts as we attempted to track changes in brain plasticity 
resulting from the unique presentation and long-term impact of this pathology. By producing an 
effective animal model that may mimic the human phenotype, we will create a platform for 
further research into SSD to increase our understanding and ultimately improve health outcomes. 
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Clinical Presentations of SSD 
SSD is a complete, or near-complete, unilateral sensorineural hearing loss that is often 
sudden in onset and permanent. SSD is typically diagnosed as an isolated problem, yet may be 
associated with other otologic signs or symptoms (Schreiber et al., 2010). The standard threshold 
of characterizing SSD in patients is evidence of audiometric thresholds that meet or exceed 90dB 
sound pressure level (SPL) in one ear. However, some also consider diagnoses of SSD patients 
to be more complex and that it should be a comparison of the hearing thresholds of both ears 
(Lucas et al., 2018). Hearing loss in general usually begins at higher frequencies, and severity 
can be classified as mild, moderate, and severe to profound (Agrawal et al., 2008). SSD is often 
described as sudden and profound in nature versus other forms of unilateral deafness that may be 
progressive or insidious in onset or nature.  
Despite the prevalence of this pathology most patients are not routinely screened for SSD 
(US Department of Health and Human Services, 1997). Rather, given the typical sudden nature 
of SSD onset, patients often present to the emergency room or primary care provider who 
eventually refer them on to an audiology or ear nose and throat specialist. It is important to 
distinguish the sudden onset (minutes to hours) nature that typically, but not always, defines 
SSD, versus the gradual onset of hearing loss that can manifest over months to years to decades.  
As such, patients suffering from SSD are usually immediately aware of the loss that is sudden 
and profound, which typically prompts them to seek medical attention. Commonly associated 
symptoms with SSD include rapid-onset tinnitus (phantom perception of sound in the absence of 
a bonafide sound stimulus), ear (aural) fullness, or feelings of blockage or fullness within the 
middle ear (Schreiber et al., 2010). Vertigo (sense of rotational movement in the absence of 
actual physical rotation) may also be reported by patients, suggesting the presence of a 
concurrent peripheral vestibular insult (Lee & Baloh, 2005) that may impact gait and general 
mobility and stability. 
 
Causes of SSD 
The etiology of SSD is unknown and may result from an inner ear viral inflammation or 
ischemia. Permanent SSD leads to long-term difficulties with sound localization and speech 
perception in noise. Untreated children are at risk for speech delays and cognitive deficits  
(Sharma et al., 2016). Commonly, these pathologies are attributed to dysfunction within the 
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cochlea, although damage to the middle or external ear can also result in this phenotype 
(Agrawal et al., 2008). Damage to the auditory nerve or cerebral cortices less commonly results 
in hearing loss, especially in loss so profound as to be quantified as deafness (Lee & Baloh, 
2005). Still, causes of hearing loss may be classified as either sensorineural (involving the inner 
ear or auditory nerve), conductive (mechanical cause leading to prevention of sound from 
reaching the inner ear) or both, termed mixed hearing loss (Bogardus et al., 2003). Patients do 
not need to have a prior history of risk factors to experience SSD, including noise exposure, head 
trauma, meningitis, ototoxic drug use, or infectious causes (i.e., syphilis). 
Causes of SSD greatly differ based on age of onset (Usami et al., 2017). Early-onset SSD 
was commonly cited to result from cochlear nerve deficiency (CNV). Other causes in early-onset 
SSD include cytomegalovirus (CMV) infection, mumps infection, and inner ear malformations 
(Simons et al., 2006). Adult SSD cases, classified as post-lingual, represent different etiologies. 
In one study, idiopathic (etiology unknown) sudden sensorineural hearing loss (SSNHL) was 
cited to be the most common etiology within adult patients (REF). Other causes include chronic 
otitis media, cholesteatoma, and ANCA-Associated Vasculitis (OMAAV). Functional hearing 
loss and cerebellar tumors were cited as less-likely causes but are still of importance as they 
require a much different approach in intervention. Finally, while a majority of early-onset 
bilateral hearing loss diseases are attributed to genetic causes, most cases of unilateral hearing 
loss are not and ultimate etiology is unknown (Morton & Nance, 2006).  
 
Prevalence of SSD 
Unique clinical presentations of SSD have encouraged the design of demographic studies 
to understand its prevalence, further improving health care delivery, screening, and 
rehabilitation. Agrawal et al. (2008) aimed to contribute to the knowledge by further 
understanding the demographics of deafness and cited differences in unilateral and bilateral 
hearing loss. They estimated that 29 million Americans between the ages of 20 to 69 experienced 
some form of hearing loss, whether unilateral or bilateral. This exceeded the cited estimate of 28 
million Americans at the time of the report, which they hypothesized was attributed to an aging 
population and the increase in exposure to damaging noise through personal devices. These 
authors also note the increased prevalence of hearing loss in adults over 70 years and recognized 
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a disproportionate level of hearing loss among males and white participants, especially in the 
third and fourth decades of life.  
Niskar et al (1998) analyzed the influence of sex, race/ethnicity, and socioeconomic 
status on hearing loss in children. While a correlation between demographics and the condition 
was inconclusive, they encouraged further research be conducted as variations in environmental 
exposure is still a likely modifying factor. Severity of hearing loss was only slight in this 
population, with unilateral hearing loss being most prevalent. Similar to older populations, more 
children were cited to experience hearing loss at higher frequencies than lower frequencies. 
Overall, the presence of deafness among a range of ages may suggest that this divergence from 
the normal phenotype is initiated at early life stages. 
 Approximately 50% of the participants in the Agrawl et al. study demonstrated 
phenotypes akin to SSD (2008). Again, male, white, and less educated participants were more 
likely to present with unilateral deafness. Despite the overlapping results in susceptible 
populations, these authors hypothesized that there is a distinction between the pathophysiological 
processes that cause unilateral and bilateral deafness.  
 A unique characteristic of SSD is its sudden presentation. Similarly, SSNHL is defined 
by an increase in hearing threshold of more than 30dB SPL over three consecutive frequencies 
within 72 hours. Hwang et al. (2017) focused on outcomes after treatment from patients 
presenting with SSNL. They determined that age may be a predictor of non-recovery after 
treatment, indicating the possible influence of demographics on onset and treatment outcomes of 
unilateral deafness. 
 It is particularly difficult to find demographic data on unilateral deafness cases; bilateral 
deafness and sudden hearing loss were among the most prominent topics of study (Agrawal et 
al., 2008; Niskar et al. 1998). The severity of the symptoms of the latter conditions may 
encourage more resources directed towards developing the literature. However, the impact of 
SSD on the daily lives of patients are more profound than a unilateral increase in threshold.  
 
Effects of SSD 
Patients with unilateral hearing loss experience major effects in the processing of the 
sound that they can recognize with the unaffected, only-hearing ear. The symmetric skull of 
humans has made binaural cues across a horizontal plane vital in sound localization (Kumpik & 
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King, 2018). Distinguishing whether a sound is in front of or behind the listener can be 
extremely difficult without intact bilateral hearing. These comparisons are also frequency 
dependent, with higher frequency sounds being more difficult to localize in space. Unilateral 
hearing loss and SSD also impairs target detection of speech, or the ability to filter background 
noise in “cocktail-party” situations. Interfering sounds are especially prominent without bilateral 
hearing, which impacts patients’ ability to multitask. 
While these incidents are especially prominent during initial periods of SSD, and 
especially with sudden SSD, patients have employed short-term strategies to improve their 
auditory experiences, even before diagnosis. Examples of this include head-turning to achieve 
direct listening in conversations and speech-reading to decipher conversations through a different 
sense (Wie et al., 2010). Patients have also been cited to eventually modify their reliance on 
binaural cues over time to improve their abilities. In both early- and late-onset SSD, 
neuroplasticity is important in calibrating neural circuits based on stimuli presentation (Kumpik 
& King, 2018). By re-weighting different spatial cues through experience and/or training, 
sensitivity to binaural spatial cues can be improved and diminish the effects of SSD. This 
evidence of neuroplasticity has fueled interest in further investigation of the impact of SSD on 
the brain. The dramatic and long-term change in stimuli presentation has allowed the research 
community to postulate this to be an important effect of the initial clinical symptoms used for 
diagnosis. The literature, and current research gaps will be discussed in a later section.  
The untoward effects on communication following SSD may significantly impact social 
interaction. The impact of their reduced abilities is a subjective experience and varies across the 
patient population (Wie et al., 2010). Still, difficulty fixating on a sound when background noise 
is present or difficulty processing speech in general can be exceedingly disabling. SSD patients 
have reported feeling excluded in conversations with multiple speakers, experiencing reduced 
well-being in social settings, and avoiding social gatherings all together. As such, SSD may lead 
to increased rates social isolation leading to or resulting from clinical depression and anxiety. 
Other consequences of SSD have also been explored. Lucas et al. (2018) found common 
themes in processing SSD within a small cohort of patients. These include worrying about losing 
their hearing in their unaffected ear, experiencing strong negative emotions such as 
embarrassment and frustration, low self-esteem, and negative coping strategies such as lack of 
motivation to complete situations that challenged their hearing ability. Interestingly, the study 
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also identified some positive impacts of the condition on patient mentality. Participants 
experienced reduced disturbance from unwanted sounds, pride in their ability to successfully 
communicate by other means, happiness in receiving support from others, and satisfaction with 
their ability to develop coping strategies. Nevertheless, the array of negative physiological and 
social consequences of SSD is substantial, especially considering the fact that patients still 
experience normal hearing in one ear. 
 
Treatments of SSD 
For permanent SSD, auditory rehabilitation options include hearing aids with 
contralateral routing of signal (CROS-HA) or bone-anchored hearing devices (BAHA) (Bishop 
& Eby, 2010). These route signals to the non-affected ear and have limited success with speech 
perception and sound localization. Only the cochlear implant (CI) offers ear-specific and central 
auditory pathway rehabilitation. CI is not consistently available for SSD in the US as insurance 
authorization criteria currently require bilateral deafness. For patients who receive a CI for SSD, 
there is large variability in hearing rehabilitation performance that may be a direct result of age, 
deafness duration and timing of implantation, all of which, may impact central auditory plasticity 
(Tokita et al., 2014). Most patients with SSD go without treatment for years and so 
understanding the potential window to intervene is highly important. 
While a cure for SSD does not currently exist, some treatments have been developed and 
analyzed for efficacy. The effects of head shadowing have been reduced by devices which re-
route sound that arrives at the impacted ear to intact, only-hearing ear (Bishop & Eby, 2010). 
Similarly, background noise can be processed to exist at a normal ratio compared to the actual 
signal through contralateral routing of signals (CROS). Cochlear implants are also available to 
support this reestablishing of a normal environment for signal processing. Only cochlear 
implants truly rehabilitate the ear and the useful aspects of binaural hearing to increase ability to 
process intensity and improve sound localization for improved speech understanding (Kitterick 
et al., 2015). 
While some CROS hearing aids may improve quality of life in SSD patients as measured 
by the HRQOL (Kitterick et al., 2015), they do not reverse symptoms or reduce difficulties with 
speech or sound localization. Furthermore, the sparse research in this area has provided limited 
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understanding into the optimal timing of treatments after SSD onset. Our work could contribute 
to understanding key mechanisms of SSD that may eventually apply to optimal treatments. 
 
SSD and Neurobiology: Long-Term Effects 
In addition to the short-term physiological changes and social disadvantages of SSD, this 
change in stimuli presentation and overall experience can result in long-term impact. As 
previously discussed, perception of auditory stimuli following unilateral deafness can change 
overtime the brain becomes acclimated to the new sensation; patients may begin to overcome the 
loss of binaural cues through other techniques subconsciously (Kumpik & King, 2018). This 
phenomenon has prompted increased investigation into changes in the brain or neuroplasticity as 
a potential primary underlying feature.  
 Neuroplasticity is generally defined as the restructuring of neural connections via 
synaptic strengthening, generation, and degradation. Different mechanisms of neuroplasticity 
exist (Glick & Sharma, 2017). Cross-modal plasticity is a form of neuroplasticity that can be a 
consequence of decreased or abnormal sensory input. Cerebral cortical regions that lose 
significant amounts of sensory input due to unilateral hearing loss become vulnerable to other 
non-auditory sensory inputs that may still be intact and arrive at that hemisphere. In addition, as 
one sensory system is partially lost, patients may begin to rely on another sense as compensation, 
as discussed by the use of speech-reading to disambiguate speech. Another form of 
neuroplasticity is intra-modal plasticity, where a particular cortical area of the brain is impacted 
by the increase or decrease in sensory input. Studies have explored which form of neuroplasticity 
is the result of auditory deprivation. Sharma & Glick (2016) collected data that supported the 
former, hypothesizing it to be a result of recruiting visual or somatosensory processing. 
However, considering the drastic change in stimuli presentation and the streamlined nature of the 
auditory pathway, intra-modal plasticity and impact to the auditory cortex is still a possibility of 
SSD (Kim et al., 2018).  
 Studies have attempted to track neuroplasticity in animal models and human patients to 
understand the impact of SSD on neural pathways. In humans, normal hearing is classified by 
symmetric auditory stimuli presentation in both ears, which sends signals to the brainstem and 
projects ipsilaterally and contralaterally within the auditory pathway (Chang et al., 2016). The 
final step of this signal transduction pathway is the accumulation of these inputs into the bilateral 
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auditory cortices. Disrupting the paired function of the two ears is what makes the short-term 
effects of SSD so drastic and is potentially what promotes reorganization of the central auditory 
pathway. Adults with normal hearing demonstrate bilateral hemisphere activation with 
dominance of the contralateral pathway (Maslin et al., 2013). In contrast, SSD and asymmetric 
hearing loss can result in shorter latencies and larger amplitudes in contralateral hemisphere 
activation compared to the ipsilateral hemisphere. Similar results of hemispheric asymmetry 
have been demonstrated thorough additional analytical tools including electroencephalography 
(EEG).  
 Animal studies have explored other techniques to demonstrate neuroplasticity of the 
auditory cortex after hearing loss. Robertson & Irvine (1989) utilized a technique to damage the 
cochlea within guinea pigs to induce partial unilateral deafness and analyzed the impact to a 
topographical map of sound frequency within the adult auditory cortex. They discovered 
significant reorganization, where neurons responded to frequencies outside of their traditional 
range. This suggested that an expansion of representative frequencies in the adult auditory cortex 
had occurred as both the lower and upper boarders of frequency range had significantly 
expanded following the trauma. Kim et al. (2018) analyzed the impact of a unilateral cochlear 
ablation surgical technique in a mouse model on neural activity using manganese-enhanced 
magnetic resonance imaging (MEMRI). The decrease in manganese on both the ipsilateral side 
(within the cochlear nucleus of the auditory cortex) and contralateral side (within the superior 
olivary complex, lateral lemniscus, and inferior colliculus) represented significantly decreased 
neural activity in their respective regions. They also witnessed a partial recovery of this response 
as the duration of the SSD model increased. Overall, these studies support the possibility of 
neuroplasticity as a modifying factor in the experience of SSD as well as the use of animal 
models in further exploring the impact of this pathology. 
 As alluded to by Kim et al. (2018) the impact of SSD can change over time. Therefore, it 
is necessary to explore the ways in which the symptoms and neural changes within the auditory 
pathway adapt overtime. Furthermore, the fact that SSD occurs in both children and adults makes 
the age of onset important in analyses. As children develop, they encounter sensitive periods 
where extrinsic sensory stimulation profoundly shapes synaptogenesis, therefore impacting the 
organization of the cortex. For the auditory cortex, peak synaptogenesis occurs between 3.5 to 4 
years of age (Sharma & Glick, 2016). Extrinsic factors will continue to refine the auditory 
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pathway for the remainder of their lives, making adult-onset cases important to study as well. 
Overall, human and animal studies have shown that reorganization of neural connections can 
occur during critical periods of development and well into adulthood when neural differentiation 
and development is complete (Kim et al., 2018; Robetson & Irvine, 1989; Glick & Sharma, 
2017; Chang et al., 2016). 
Understanding the impact of SSD and unilateral hearing loss on cortical regions is crucial 
as it impacts treatment outcomes. As noted previously, treatments of this pathology have 
extended to cochlear implants in an attempt to restore the functionality of the impacted ear rather 
than rerouting stimuli to the intact ear. The success of this treatment approach is dependent on 
whether the impacted ear is salvageable after dormancy. Studies have already begun to 
demonstrate the disappearance of contralateral dominance in the auditory cortex after unilateral 
hearing loss (Kim et al., 2018). With this knowledge, the question now lies in what extent this 
reorganization occurs and whether there is an optimal time window for intervention. 
Furthermore, understanding whether reorganization occurs within the auditory cortex alone or if 
it is accompanied by other cortical areas that process sensory information (i.e. visual cortex, 
somatosensory cortex, etc.) is necessary to account for the impact of sudden restoration of 
bilateral hearing to our general neurobiology and sensory systems. 
 
Creating an Animal Model of SSD 
Despite the existence of these data, there still exists a large gap in the literature regarding 
the impact of SSD on neuroplasticity and long-term effects that would ultimately influence the 
development of treatments and their outcomes (Kim et al., 2018). 
The Kresge Hearing Research Institute at the University of Michigan has recognized the 
vitality of an intact auditory system on quality of life. Efforts through the laboratory of Dr. 
Gregory Basura have previously worked to understand the mechanisms of tinnitus through a 
collection of anatomical and physiological studies within animal models. Recognizing the 
prevalence of SSD cases in the Otolaryngology Department in the University of Michigan Health 
System, we utilized similar methodologies to gain insight into neurological characteristics 
impacted by SSD.  
We attempted to contribute to the understanding of the impact of SSD on the primary 
auditory cortex (A1) as it is a crucial point in the auditory processing pathway. We focused on 
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A1 as there is an obvious change to auditory presentation with this disorder and ambiguity in the 
changes in other senses after unilateral deafness.  
An animal model that mimics the human condition of sudden onset SSD is needed to 
better characterize the changes in central auditory circuits after the insult. Our study was 
designed to provide a reliable representation of SSD to the field using diphtheria toxin receptor 
(DTR) mediated targeted cell ablation in a mouse model. Destroying hair cells within the inner 
ear through this technique allowed us to avoid confounding variables cited in other animal 
models (Kim et al., 2018; Robertson & Irvine, 1989). Ultimately, future studies will be able to 
better define etiology of SSD and its effects. This will improve current outcomes and inspire the 
design of new, more effective treatments.  
 
Evaluating A1 Plasticity After SSD 
Cerebral cortex plasticity is often mediated by acetylcholine. Receptors of this 
neuromodulator can be classified as either nicotinic or muscarinic and both exist on excitatory 
and inhibitory neurons in the central auditory system, including within the auditory cortex (Deng 
et al., 2015). Nicotinic acetylcholine receptors are ionotropic, while muscarinic acetylcholine 
receptors are metabotropic members of the G protein-coupled receptor family. While both 
receptor types are present in the cerebral cortex, nicotinic receptors have been recorded at 
constant levels throughout cortical development while muscarinic receptor expression peaks at 
specific intervals (Shideler & Yan, 2010). This has led many to classify muscarinic acetylcholine 
receptors as especially critical for development, maturation, and ongoing modification the cortex.  
Our study used [3H]scopolamine, a muscarinic acetylcholine receptor antagonist, in 
radioligand binding assays as it has the ability to pass through the blood brain barrier and bind to 
muscarinic receptors in the central nervous system (Klinkenberg & Blokland, 2010). This 
strategy allowed us to identify changes in muscarinic receptor density within A1 resulting from 
sudden and rapid unilateral deafness. 
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Materials and Methods 
 
Mice Preparation and Background 
Mice are an ideal species to develop a possible model for SSD as they have undergone 
many genetic manipulations that provide opportunities to mimic human conditions. As such, we 
used a mouse model and technique developed by Golub et al. (2012) to produce transgenic mice 
with the ability to conditionally and selectively destroy hair cells in the adult mouse cochlea with 
the injection of diphtheria toxin (DT) via surgery protocol. In this mouse model, expression of 
the human diphtheria toxin receptor (DTR) gene is driven by the promoter for Pou4f3, a gene 
selectively expressed in cochlear hair cells. Systemic injection of diphtheria toxin (DT) in these 
mice results in profound loss of cochlear hair cells and bilateral deafness, without inducing 
damage to spiral ganglion neurons or other parts of the cochlea. 
To breed Pou4f3DTR mice, we crossed heterozygous Pou4f3DTR mice (Jackson Labs stock 
# 028673) with wild-type C57BL6/J mice. In total, we used five (5) DTR mice and six (6) 
control mice (sham mice) for our study. DTR mice were congenic with the C57BL6/J 
background and sham mice were of C57BL6 background. Ages of the mice (based from first 
ABR reading) ranged from P45 to P58 (exception of Treatment 1 mice (2) being P139), with 
sham mice being less variable and complications in breeding resulting in a more variable age 
range within DTR mice. Sham mice were also exclusively male in an attempt to reduce 
confounding variables. The difficulty in breeding with DTR mice resulted in breeding of female 
models to mediate effects of the DTR gene (DTRxC57BL6/J). DTR mice also exhibited higher 
mortality rates and different behavioral patterns, including difficulty in anesthetization prior to 
surgery. Otherwise, this model was cooperative with our surgical methods, specifically with our 
use of DT. All mouse experiments were approved by the University of Michigan Institutional 
Animal Care and Use Committee (protocol # PRO00006642) and were in accordance with NIH 
guidelines for the care and use of laboratory animals. 
 
Auditory Brainstem Response Testing 
Auditory Brainstem Response (ABR) testing produces an objective measure of hearing 
function (Melcher et al., 1996b). These recordings are collected by relatively noninvasive means, 
making it a credible tool among animals and humans. The signals produced represent an evoked 
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response from auditory nerve and brainstem auditory pathway activity (Figure 1). Synchronous 
activity from these groups of nerves is produced by a stimulus, here represented by a click, with 
activity large enough to shadow any competing background noise from the ABR recording 
(Melcher et al., 1996a).  
 
 
 
 
Figure 1. Example of waveforms produced by auditory brain response (ABR) testing. From 
Treatment 2 mouse recording at 8 kHz. Level dB on the left side represents the decibel level of the 
tone in the mouse’s ear. Roman numerals are used to label waves representing different fiber 
activity or cellular activity within the auditory system.  Wave I: auditory nerve fiber activity. Wave 
II: neural activity from the cochlear nucleus. Wave III-IV: activity from higher auditory brainstem 
locations (lateral and medial olivary complexes and lateral lemniscus) resulting from activity in 
the cochlear nucleus. Wave V: neural activity from the inferior colliculus. 
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To verify the initial presence of normal auditory functioning and post-surgical unilateral 
hearing loss, ABR testing was conducted three weeks before surgery and after the 10-day 
recovery period after surgery. Mice were anesthetized with an initial intraperitoneal injection of 
ketamine/xylazine cocktail (100 mg/kg ketamine, 10 mg/kg xylazine) and maintained under deep 
anesthesia via administration of maintenance doses of ketamine (33 mg/kg) as needed throughout 
the readings.  
Further preparations, configurations, and interpretation of output signals aligned with 
Melcher et al. (1996) studies under the titles “Generators of the brainstem auditory evoked 
potential in cat. I.” and “Generators of the brainstem auditory evoked potential in cat. II.” 
Animals were placed on a heating pad within the sound proof recording booth to maintain body 
temperature. Three electrodes were inserted under the skin in the following positions: (1) the 
vertex, (2) the right ear, and (3) the left ear. Further research on electrode placement encouraged 
us to use the configuration adopted by Shaneen et al. (2015). See Figure 2. Sound was delivered 
to each ear independently though the use of a calibrated speaker, which administered 4 ms tone 
pips at a rate of 40/s.  
 
 
 
Figure 2. From Shaneen et al. (2010). Schematic of electrode configuration for ABRs. Pinna to 
pinna configurations used positive electrode placed in identical location on contralateral side (not 
shown).  
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A major modification of the technique outlined by Melcher et al. (1996a) included the 
range of frequencies analyzed for our study. To encompass a wide spectrum of frequencies within 
the mouse model, we used 8, 16, and 32Hz signals. Based on a collection of literature also cited 
by Melcher et al. (1996a), we considered 40dB SPL to be the threshold for hearing. Threshold was 
defined as “the lowest level that could elicit a visually detectable neural response.” Of note, signals 
were subjectively read rather than computationally analyzed considering the nature of our study. 
Our main goal was to verify the presence or loss of auditory functioning. The limits of our 
equipment capped our maximum volume at 110dB SPL. An ear was considered successfully 
deafened when it showed no signal at around 100dB SPL. 
 
Posterior Semicircular Canal Surgery 
Our largest barrier to further understanding the impact of SSD on A1 muscarinic receptor 
density has been the design of a reliable animal model with the ability to exhibit unilateral 
hearing loss without loss of spiral ganglion neurons during its adult life. This sudden loss beyond 
the critical stages of development is an important feature of our model as it would reflect the 
human phenotype.  
Suzuki et al. (2017) designed a procedure that successfully delivered adeno-associated 
virus (AAV) injections into the posterior semicircular canal into an adult mouse without major 
complication, including threshold shifts, suprathreshold dysfunction, or hair cell damage. A post-
auricular incision and blunt dissection of the thin muscle layers overlying the temporal bone 
allowed them to spot clear landmarks to determine the location of the canal. A 26-gauge 
hypodermic needle and microcatheter were utilized to administer the injection. This procedure 
provided us with a supported approach in designing a vector to deliver toxin into the posterior 
semicircular canal (PSCC).  
After verifying animals exhibited normal hearing thresholds, surgical preparations were 
completed. Sterile drapes were used to cover the workspace. Tools were sterilized via autoclave. 
A heating pad was placed over the surgery bed and covered with a paper towel to avoid over-
heating. Temperature was monitored via rectal probe. A nose cone was also attached to the 
surgery bed to continually administer isoflurane anesthesia during the procedure. As in Suzuki et 
al. (2017), a cannula connected to a pressure injector (Nanoject system) was utilized to inject 
diphtheria toxin (DT) into the posterior canal.  
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Animals were first anesthetized in a chamber regulated with 1.5% oxygen and 3% 
isoflurane for 3-5 minutes. After anesthesia induction, animals were placed on surgery bed and 
within the nose cone, and their eyes protected with artificial tears ointment. Carprofen (5 mg/kg) 
and buprenorphine (0.1 mg/kg) were injected subcutaneously. Anesthesia was decreased to 1% 
oxygen and 2% isoflurane. The surgical area (behind the pinna) was shaved and sterilized with 
three alternating washes of iodine and ethanol. A small incision was made to the skin to reveal 
the muscles and region of interest. Similar landmarks in the Suzuki et al. (2017) procedure were 
noted to find the PSCC. Special care was made to prevent damage to the muscles. A #11 scalpel 
was used to create a ridge on the bone for the 26-gauge needle, which was then rotated to create 
a substantial hole within the bone for the cannula. The cannula was placed and used to inject 
approximately 250nl throughout a span of five minutes, delivering a total dose of 1.25ng DT. 
The cannula was kept in the area for an extra five minutes following injection. A small piece of 
muscle was placed inside the hole within the bone and surrounding muscles were moved back 
into place before suturing. Lidocaine was administered over the surgical wound. Mice were then 
placed in recovery and verified as responsive before return to home cage. In accordance with 
guidelines from the Institutional Animal Care and Use Committee (IACUC), animals were 
routinely monitored and fed diet gel throughout the recovery period. 
Control mice also underwent anesthetization through the same parameters and were 
sham-operated. The surgical area was shaved and an incision was made. However, no opening 
was made in the PSCC. The wound was sutured and lidocaine was administered. Recovery 
protocol was followed as described above. 
 
Tissue Preparation 
After deep anesthetization by isoflurane in an isoflurane drop jar, animals were sacrificed 
by decapitation and brains were rapidly dissected. Brains were removed and snap frozen in 
isopentane at 20C and stored at -80C until ready for use.  
Standard sectioning procedure was completed to prepare slides for autoradiography 
experiments. Frozen mice brains were thawed from -80C and sliced at 20m using Bright 
Instruments cryostat set to -18C. Location of A1 was determined through major neurobiological 
landmarks (Figure 3). Tissue was thaw-mounted on the 1x3 inch poly-L-lysine subbed glass 
slides until processed for radio-ligand binding. 
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Figure 3. Location of Primary Auditory Cortex (A1) within the mouse brain. 
 
 
[3H]Scopolamine Receptor Autoradiography  
As outlined by Frey and Howland (1992), coronal brain sections containing A1 used for 
autoradiography experiments were pre-conditioned for 5 min with phosphate buffer saline (PBS) 
pH 7.4. Sections were transferred to a solution of [3H]scopolamine in PBS pH 7.4 and incubated 
for 30 min. Subsequently, [3H]scopolamine-labeled tissue sections were washed with PBS pH 
7.4 for 2×5 min and rinsed with deionized H2O for approximately 5 sec. Finally, all slides were 
dried at room temperature before being exposed to a tritium-sensitive phosphoimager screen 
(Fuji) for 3 days. The screen was read in a GE Healthcare Typhoon FLA 7000.  
 
Optical Density and Statistical Analysis 
Densitometry of the phosphoimager screen was performed with the ImageQuant 
program. Considering our interest in A1, analysis was focused on this region, as demonstrated by 
Figure 4. The Allen Mouse Brain Coronal Atlas (2011) was used to determine the location of A1. 
Receptor density was calculated from co-exposed standards (considering background) and 
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converted to fmol/g protein using a standard curve. Once conversions were completed and 
background non-interference was verified, contralateral (right) A1 densities were compared to 
ipsilateral (left) A1 densities using a linear mixed model via LME4 library on R Commander. 
We considered significance to be present at p  0.1. 
 
 
 
Figure 4. Examples of outlines drawn around primary auditory cortex (A1) in coronal slices of 
mouse brains to determine optical density in densitometry analysis. 
 
 
Results 
 
Threshold Shifts Represented by ABR Testing 
Before PSCC Surgery.  All mice injected with DT (experimental) and control (sham) 
groups produced normal ABR responses before PSCC surgery. This verified the presence of 
normal auditory function within the mice prior to experiments.  
After PSCC Surgery. After the three-week period of recovery post-surgery, sham mice 
did not demonstrate an ABR threshold shift and did not show any effects of anesthesia alone on 
hearing thresholds. Because the exact concentration of DT to achieve SSD is currently not 
known, experimental mice received different concentrations of DT (Table 1). The experimental 
mouse exposed to treatment 3 demonstrated a shift in ABR threshold in the surgically injected 
left ear at 8kHz (30dB SPL to >110dB SPL) and 16kHz (60dB SPL to >110dB SPL). At 32kHz, 
this mouse presented with thresholds greater than 110dB SPL before and after surgery. No 
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threshold changes were observed in the right ear (Figure 5). The experimental mouse exposed to 
treatment 4 demonstrated intact hearing before surgery. However, we could not record ABR 
responses after surgery as it was difficult to anesthetize this particular animal with our 
ketamine/xylazine cocktail.  
 
 
Animal Group [DT] (mg/ml) 
Treatment 1 0.01 
Treatment 2 0.025 
Treatment 3 0.05 
Treatment 4 0.1 
 
Table 1. Concentration of diphtheria toxin (DT) used in PSCC surgery on different experimental 
animal groups. 
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Figure 5. Treatment 3 mouse thresholds of surgically injected (left) ear (above) and non-involved 
(non-injected) (right) ear (below) before and after surgery recorded via ABR testing. 
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[3H]Scopolamine Binding in A1 
 After surgeries and brain harvesting, autoradiography studies of the six (6) sham animal 
brains demonstrated no significant changes within in A1 optical density measures of 
[3H]scopolamine binding when comparing the contralateral (right) and ipsilateral (left) 
hemispheres (Figure 6). 
 Within the experimental animals, various treatments were classified by the concentration 
of DT used on the animals (Table 1). Mice within treatments 1 (p = 0.3028), treatment 2 (p = 
0.7893), and treatment 3 (p = 0.5982) groups did not demonstrate significant difference in 
receptor expression between the contralateral and ipsilateral A1. The mouse in treatment 4 did 
demonstrate a strong trend toward a difference in receptor expression (p = 0.0865) between the 
contralateral hemisphere and ipsilateral hemisphere, with the contralateral A1 demonstrating 
significantly higher muscarinic receptor expression upon binding with [3H]scopolamine (Figure 
7). 
 
 
Figure 6. Comparison of optical densities (fmol/g) of ipsilateral (left) A1 versus contralateral 
(right) A1 in control mice after exposure to muscarinic acetylcholine receptor antagonist 
[3H]scopolamine. 
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Figure 7. Comparison of optical densities (fmol/g) of ipsilateral (left) A1 versus contralateral 
(right) A1 in experimental mice after exposure to muscarinic acetylcholine receptor antagonist 
[3H]scopolamine (p  0.1). 
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Discussion 
 
 This study attempted to quantify changes in A1 muscarinic receptor density in a possible 
animal model of SSD utilizing DTR. Our data represents the possibility for the successful 
development of this novel model for this study and others. It also suggests the likelihood of 
witnessing changes in muscarinic receptor density after sudden-onset unilateral hearing loss. The 
development of these methods will allow us to continue to understand patterns of neuroplasticity 
in A1 after the onset of SSD.   
 
Creating a Model for SSD Using DTR Mice 
 To understand the impact of SSD on A1, we needed to produce a reliable animal model 
to represent the phenotype present in humans. Considering current knowledge on the causes of 
SSD in patients, we determined that targeted cochlear hair cell ablation would produce the most 
accurate representation. Previous studies have developed models with partial unilateral deafness 
or SSD by directly impacting the cochlea. Robertson & Irvine (1989), induced the former 
through direct mechanical lesion of a restricted portion of the Organ of Corti. Lee et al. (2017), 
induced SSD by disrupting the bony wall of basal turn of the cochlea using a 26-guage needle 
and followed with irrigation of saline through the perforation to clear the region. Direct trauma to 
this region is difficult to guarantee. Kim et al. (2018), utilized a more concrete landmark by 
dissecting the otic bulla to reach the cochlea to avoid impacting the facial nerve. But even when 
care is taken to avoid impacting other regions, these techniques suggest that SSD is solely 
induced by trauma to the effected ear. In reality, the causes are much more diverse and complex. 
Jakob et al. (2015) utilized a similar approach to our study. They injected ototoxic 
aminoglycoside antibiotic neomycin into the inner ear to destroy cochlear hair cells. While 
effective, this technique was only demonstrated in mice at postnatal day 10, when the meatus and 
mesenchyme in the middle ear is still closed and preventing auditory function. Moreover, this 
technique induced bilateral hearing loss rather than unilateral hearing loss. 
 A more accurate representation of SSD will allow us to better understand the gaps in our 
knowledge on SSD. The methods outlined by Golub et al. (2012), proved to be noteworthy as 
they utilized intramuscular injections of DT to produce bilateral hearing loss of cochlear hair 
cells. Our study modified their techniques to be the first attempt at unilateral hair cell ablation. 
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The adult mouse that underwent treatment 3 surgical conditions in our study showed evidence of 
impacted hearing in the left ear at frequencies of 8kHz and 16kHz and intact hearing in the right, 
non-surgical ear via ABRs. We were unable to collect recordings from the mouse in treatment 4 
due to it being unaffected by our maximum doses of anesthesia. However, it is likely that the 
increased concentration of DT provided at least the same deafening pattern as in treatment 3. 
These findings justify future studies that continue to explore the nuances of this technique and its 
application to our understanding of neuroplasticity throughout the cortex as a result of SSD. 
 Advantages. This approach allows us to induce SSD rapidly and in adult models to 
parallel the onset in human patients. In our small sample size, experimental surgeries were 
completed within an hour and produced mice that had no major issues during the recovery period 
or behavioral changes that did not already align with unilateral deafness. Therefore, our model is 
fast, safe, and has the potential to be extremely effective in destroying most hair cells. Further 
investigation to determine the optimal dose of the DTR required to induced SSD and the timing 
of SSD-onset after the injection are needed to better characterize the model before it can be 
implemented widely in future studies.  
 Disadvantages. As such, the development of this novel mouse model must be critically 
examined for validity and for the design of future studies. The largest struggle in managing and 
maintaining this model came from the incorporation of the DTR system. Since its development 
in 2002, this technique has been used to ablate distinct cell types, especially in the immune 
system (Ruedl & Jung, 2018). Our model crossed DTR and C57BL/6 in an attempt to mitigate 
the behavioral abnormalities that characterize homozygous DTR mutant animals. C57BL/6 
animals have also been cited to develop severe age-related hearing loss, potentially introducing 
another variable into our study (Konishi et al., 2017). Even with this precautious measure, we 
still noted strange behaviors within the experimental mice. Their behaviors were not abnormal in 
the sense where it impacted recovery, but instead impacted their handling and recordings. 
Several of the animals were too active to handle and anesthetize, and even within those that were 
successfully injected, some were difficult to fully anesthetize for the ABR recordings. 
Still, many of these reported shortcomings have been cited among limitations with 
transgenic approaches in general (Ruedl & Jung, 2018). Therefore, efforts should be made to 
overcome these challenges rather than considering this approach useless. 
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Auditory Brainstem Response Technique 
We utilized ABR testing to verify the presence of intact hearing in our animal population 
before surgeries and the impact of sham-surgery or PSSC surgery on the sham and experimental 
animals, respectively. The ABR is an objective measure of hearing function that can be 
registered relatively noninvasively in animals and humans. The presence of a repetitive tone, 
noise burst, or click stimulus results in the synchronous firing of cells in the auditory nerve and 
brainstem. These responses are quantitatively averaged using far-field electrophysiology to avoid 
the influence of background neural and physiological noise. The resulting waveform contains 
peaks which represent different fiber or cell activity within the auditory pathway. Studies have 
been conducted to overlay neural activity with individual peaks (Melcher et al., 1996b).  
 Damage to the auditory pathway will result in changes within the ABR recordings. 
Typically, this results in an increase in threshold, as we recognized in treatment 3 and treatment 
4 experimental mice who underwent targeted cochlear ablation cell therapy. Other pathologies 
may impact the latency and amplitude of these waveforms. For example, sensorineural hearing 
loss (SSNL) can be recognized through a significant change in inter-peak intervals (Hwang et al., 
2017). Furthermore, the extent to which a peak or an entire waveform is impacted may depend 
on the level of damage sustained by the pathway. Therefore, it is possible that a mouse may 
undergo a change in hair cell number after injection with DT and that the loss is significant 
enough to be recognized by the animal but not enough to be noted through ABR testing. This 
may have been a result of the experimental mice in treatment 1 and treatment 2.  
 
Acetylcholine Modulating A1 
 Neuroplasticity in the adult cortex can occur in response to learning or to peripheral 
injury. Within A1, neurons have frequency-selective fields that can be modified in response to 
pairing of an auditory stimulus with a somatosensory stimulus (Banderwoski et al., 2001). 
Acetylcholine is the neurotransmitter which modulates the reorganization of synapses in 
response to these events. This has been highlighted in experiments which pair a tone with an 
iontophoretic injection of acetylcholine and record a larger response as a result compared to 
unpaired tones. What is defined as significant enough to elicit changes to receptive fields is not 
fully understood in the auditory system or otherwise. 
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 Evidence suggests acetylcholine to be a critical component in neuroplasticity mechanisms 
(Bandrowski et al., 2001). Studies have recognized that upon release of acetylcholine into the 
cortex by stimulation of the nucleus basalis, an increase in excitatory postsynaptic potential 
(EPSP) amplitude and probability of neuronal discharge is present. Muscarinic acetylcholine 
receptors in particular have been noted in the process of reducing inhibitory postsynaptic 
potentials (IPSPs) to contribute in EPSP amplitude elevation. Finally, acetylcholine is classically 
known to depolarize membranes and increase cellular excitability. This evidence supports the 
importance of acetylcholine-dependent mechanisms in the modification of A1.  
To track neuroplasticity changes associated with acetylcholine and further understand the 
results of specific stimuli presentation, we used [3H]scopolamine to quantify muscarinic 
acetylcholine receptor expression in A1. Our results showed no significant changes but do 
demonstrate a strong trend towards a difference in receptor expression at a high dose of DT, 
likely destroying most cochlear hair cells out of all of the experimental animals in our study. The 
effect of this change in phenotype, as the most likely representation of SSD, will be discussed in 
further detail in this context.    
 
SSD and its Effect on A1 
The cerebral cortex can alter synaptic connections within the auditory pathway outside of 
critical periods of development (Sharma & Glick, 2016). In humans with SSD, changes in 
auditory experience over time suggest this to be a possible phenomenon as stimuli presentation 
and any associated learning processes have changed.  
 Our results in adult mice support the notion that neuroplasticity is an active mechanism 
throughout the lifespan of an animal. We recognized more drastic changes in muscarinic 
acetylcholine receptor expression in animals who received a larger dose of DT during PSCC 
surgery. This technique should destroy a larger quantity of hair cells and more significantly 
impact auditory perceptions, as we noted in ABR testing in these higher-dose treated animals. 
That is not to say that no hair cells were ablated in the lower-dose treatments, but that their 
thresholds did not reach that defined by our study. Therefore, it is possible that auditory function 
was impacted in these other treatments as well.  
Drawing from this hypothesis, we still notice no significant changes in muscarinic 
acetylcholine receptor density between the contralateral and ipsilateral hemispheres within 
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treatments. The largest dose of DT withstood by an animal produced a result that demonstrated a 
strong trend toward a difference in receptor expression, which may suggest that the mechanisms 
of neuroplasticity are only present upon significant changes in stimuli presentation. Future 
studies should continue exploring the correlation between changes in stimulus presentation in all 
senses and neuroplasticity.  
It is possible that conditions of mice in future studies will produce significant data 
representing a down-regulation of muscarinic acetylcholine expression in the ipsilateral 
hemisphere compared to the contralateral hemisphere, as was alluded to by the treatment 4 
mouse in our study. The replication of these results would suggest that muscarinic receptors, and 
the neurons they inhabit, are susceptible to noise trauma. In particular [3H]scopolamine binds to 
multiple subtypes but is especially attracted to M1 and M2 receptors (Frey & Howland, 1992). 
Therefore, we can attribute possible down-regulation to these muscarinic receptor types, 
narrowing our understanding of neuroplasticity in A1. Still, as [3H]scopolamine does bind with 
lower affinity to other muscarinic acetylcholine subtypes (M3-M5), further studies will need to 
use more specific radioligands to differentiate these subtypes and properly track changes in 
receptor density (Levey et al., 1991). 
Of note, we did notice potential down-regulation in the ipsilateral hemisphere rather than 
the contralateral hemisphere, as one may anticipate due to the decrease in sensory input. The 
crossing-over of sensory information to the contralateral hemisphere makes the latter hypothesis 
more plausible as cochlear damage would disrupt the central auditory pathway (Pickles, 2015). 
Still, some sensory information can be conserved on the ipsilateral side and may be more 
dominant in these mechanisms. Further studies should verify that a decrease in ipsilateral 
receptor density is the definite change in neuroplasticity resulting from the onset of SSD. 
Understanding that projections from the inner ear exist in both the contralateral and 
ipsilateral hemispheres, mechanisms that may result in general down-regulation of muscarinic 
acetylcholine receptors include neuronal cell death, changes in post-translational processing, and 
activity-dependent changes mediated by acetylcholine. Neuronal cell death is plausible as the 
deafening of the left ear involved the death of cochlear hair cells, potentially destroying original 
pathways downstream. In addition, cellular expression of proteins within the neurons of these 
pathways may have been impacted by the deafening by damaging messenger RNA (mRNA), 
which has been shown to impact receptor expression following cerebral cortical damage (Kobori 
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et al., 2002). Finally, changes in cholinergic inputs following deafness may influence muscarinic 
acetylcholine expression on pre-synaptic and/or post-synaptic neurons. The accumulation of 
large amounts of acetylcholine following trauma may result in the down-regulation of these 
receptors, as has been noted in NMDA glutamate receptor feedback modulating synaptic 
reorganization following disease and trauma (Scheetz & Constantine-Paton, 1994). Future 
studies should be aimed at narrowing this list of hypotheses to determine definite causes of 
changes in A1 muscarinic receptor expression. 
 
Future Directions 
 We noted a strong trend towards a difference in muscarinic acetylcholine receptor 
expression within the adult mouse in treatment 4. This mouse, although unrecorded, likely 
exhibited SSD symptoms within the left ear. The mouse that underwent a less-concentrated dose 
of DT in treatment 3 also demonstrated signs of unilateral hearing loss in the left ear but no 
changes in muscarinic receptor density between the contralateral and ipsilateral hemispheres. 
Mice in treatment 1 and 2 did not demonstrate hearing loss or changes in receptor density. The 
time limit of this study prevented the administration of other, varying treatments of DT. 
Nevertheless, the current data suggests these outcomes to be conducted by a dose-dependent 
mechanism. Future studies should continue exploring other treatments to develop a dose-
response curve and to identify an optimal dose for the studying of neuroplasticity in A1. 
 
Limitations 
 Our study was limited by several variables. As such, additional data is required before we 
can draw firm conclusions. While we initially intended to maintain an all-male animal population 
for our studies, DTR animals were both male and female due to the difficulty in breeding adult 
mice with this strain. We only had the capacity to run a small number of sham (n=6) and 
experimental (n=5) animals. Furthermore, several doses of DT were used in these animals as we 
worked to determine an optimal dosage to represent the phenotype of SSD, making the number 
of animals exposed to each treatment even smaller. 
 Within our radioligand binding assays, we recognize that [3H]scopolamine binding is 
limited; it is unable to label all muscarinic receptors despite highly concentrated and long-term 
exposure to the tissues. Densitometry analysis in this study was focused on A1 but did not 
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consider the different layers of the cortex and the differences in optical density within them 
considering the preliminary nature of the study. Our use of [3H]scopolamine on mouse tissue 
also made this consideration difficult as the picture produced from the phosphoimager screen is 
not sharp enough to easily distinguish cortex layers. Further studies that utilize this ligand could 
co-label cell types to mitigate this issue, using techniques such as in-situ hybridization or 
immunochemistry.  
 
Conclusion 
 In summary, these data support the DTR mouse as a potential model of SSD witnessed in 
human patients as it has the ability to replicate characteristics associated with the pathology. The 
injection of DT into the PSCC of the left ear resulted in the targeted ablation of hair cells to 
represent the sudden-onset, unilateral nature of SSD. We were successful in inducing unilateral 
deafness in animals exposed to 0.1 mg/ml and 0.05 mg/ml concentrations of DT during PSCC 
surgery. By analyzing muscarinic receptor density using radio-ligand binding techniques, we 
further explored the impact of SSD deafness on central auditory pathways and found a strong 
trend towards a difference in muscarinic receptor expression in the hemispheres of the brain, 
specifically thorough a down-regulation in ipsilateral hemisphere receptor density. This was 
witnessed in the animal treated with the highest concentration of DT in our study (0.1 mg/ml). 
These data contribute to proving the validity of this model, which will ultimately jumpstart 
future studies to add to the growing literature on SSD. Our model has the potential to be used to 
better understand neuroplasticity in A1 resulting from SSD.  
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